


Curriculum Vitae

Name	Nicolas Girard	
Current Position & Affiliation	Head of Thoracic Oncology, Thorax Institute Curie Montsouris, Paris and Professor of Thoracic Oncology, Paris Saclay University	
Country	France	

Educational Background

- 1993-1996: College, Bachelor in Mathematics, Lycée Remi-Belleau, Nogent le Rotrou, France
- 1996-2005: M.D., Claude Bernard University, Lyon, France
- 1998-2002: M. Sc. Biological and Medical Science, Parasitology, Rabelais University, Tours, France
- 2005-2006: M. Sc. Cellular and Molecular Biology, Claude Bernard University, Lyon, France
- 2007: Certification in Internal Medicine, Very Honourable distinction
- 2007: Certification in Respiratory Medicine, Very Honourable distinction
- 2011: Certification in Medical Oncology
- 2011: PhD., Claude Bernard University, Lyon, France
- 2012: Certification in Research “HDR”

Professional Experience

- 1998-2002: Medical Student, University Regional Hospital, Tours, France
- 2002-2004: Resident in Internal Medicine, Hospices Civils de Lyon, Lyon, France
- 2004-2005: Resident in Medical Oncology, Hospices Civils de Lyon, Lyon, France
- 2005-2006: Master student, Claude Bernard University, Lyon, France
- 2006-2007: Resident in Respiratory Medicine, Hospices Civils de Lyon, Lyon, France
- 2007: Junior Fellow, Thoracic Oncology Unit, University Regional Hospital, Besançon, France
- 2007-2009: Research Fellow, Pao Laboratory, Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center, New-York, NY, US

- 2009-2013: Post-doctoral Fellow, Claude Bernard University, Lyon, France
- 2009-2011: Clinical Fellow, Respiratory Medicine, Thoracic Oncology, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
- 2011-2013: Assistant Attending, Respiratory

Professional Organizations

Local networks

- 2017- : Head of the Thorax Curie-Montsouris, Institut Curie, Institut Mutualiste Montsouris, Paris

The institute is based on a partnership between Institute Curie and Institute Montsouris.

About 1400 new patients with lung cancer are seen every year. A diagnostic unit dedicated to nodules has been set up.

National networks

- 2017- : Administrator, Treasurer of the French Thoracic Cancer Intergroup
- 2017- : Secretary of the Oncology Group of the French Respiratory Medicine Society
- 2011- : Associated coordinator of the Expert National Center for thymic RYTHMIC Tumeurs Thymiques et Cancer

International networks

- 2020- : President Elected of the International Thymic Malignancy Interest Group,
- 2018- : Chair of the M subcommittee of the Staging and Prognostic Factors Committee Thymic domain de l'International Association for the Study of Lung Cancer (IASLC)
- 2017- : Head of the Thoracic Tumors Domain (G8) of the European Reference Network EURACAN
- 2017- : Administrator of consortium WIN Worldwide Innovative Networking

Main Scientific Publications

Scientific articles

International journals

1. F. Mornex, N. Girard, C. Béziat, A. Kubas, M. Khodri, C. Trépo, P. Merle. Feasibility and efficacy of highdose 3-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies – Mature results of the French phase II RTF-1 trial. *Int J Radiat Biophys Oncol* 2006;66:1152-8
2. F. Mornex, N. Girard, JY. Scoazec, N. Bossard, M. Ychou, D. Smith, JF. Seitz, PJ. Valette, C. Mercier, P. Rouanet, M. Ducreux, C. Partensky. Feasibility of pre-operative combined radiation therapy and chemotherapy with 5-fluorouracile and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 phase II trial. *Int J Radiat Biophys Oncol* 2006;65:1471-8
3. N. Girard, V. Cottin, F. Tronc, B. Etienne-Mastroianni, F. Thivolet-Béjui, J. Guyotat, PJ. Souquet, JF. Cordier. Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. *Lung cancer* 2006;53:51-8
4. F. Huguet, N. Girard (co-first author), C. Seblain-El-Guerche, C. Hennequin, D. Azria. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. *J Clin Oncol* 2009 ;27:2269-77
5. R. Le Scodan, F. Mornex, N. Girard, C. Mercier, PJ. Valette, M. Ychou, F. Bibeau, P. Roy, JY. Scoazec, C. Partensky. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors. Analysis of the SFRO-FFCD 9704 trial and literature review. *Ann Oncol* 2009;20:1387-96
6. N. Girard, I. Ostrovnaya, C. Lau, B. Park, M. Ladanyi, D. Finley, C. Deshpande, V. Rusch, I. Orlov, WD. Travis , W. Pao, CB. Begg. Genomic and mutational profiling to assess clonal relationships between 10 multiple non-small cell lung cancers. *Clin Cancer Res* 2009 ;15:5184-90
7. N. Girard, F. Mornex, N. Bossard , M. Ychou, B. Chauffert, V. Wautot. Estimating the optimal dose of twice-weekly gemcitabine for concurrent chemoradiation in unresectable pancreatic carcinoma: mature results of the GEMRT-01 phase I trial. *Int J Radiat Biophys Oncol* 2010; 77:1426-32
8. N. Girard, C. Deshpande, C. Lau, D. Finley, VW. Rusch, W. Pao, WD. Travis. Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases. *Am J Surg Pathol* 2009;33:1752-64

9. N. Girard, P. Jacoulet, M. Gainet, R. Elleuch, D. Pernet, A. Depierre, JC. Dalphin, V. Westeel. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. *J Thor Oncol* 2009;4:1544-9
10. N. Girard, R. Shen, T. Guo, MF. Zakowski, A. Heguy, GJ. Riely, J. Huang, C. Lau, AE. Lash, M. Ladanyi, A. Viale, C. Antonescu, WD. Travis, VW. Rusch, MG. Kris, W. Pao. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. *Clin Cancer Res* 2009 ;15 :6790-9
11. N. Girard, C. Deshpande, CG. Azzoli, V. Rusch, WD. Travis, M. Ladanyi, W. Pao. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. *Chest* 2009;137;46-52.
12. N. Girard, E. Lou, CG. Azzoli, R. Reddy, M. Robson, M. Harlan, I. Orlov, Y. Yatabe, K. Nafa, M. Ladanyi, A. Viale, MG. Kris, G. Riely, V. Miller, RJ. Klein, K. Matsuo, W. Pao. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. *Clin Cancer Res* 2010;16:755-63
13. N. Girard, F. Mornex, JY. Douillard, N. Bossard, E. Quoix, V. Beckendorf, D. Grunenwald, E. Amour, B. Milleron. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. *Lung Cancer* 2010;69:86-93
14. N. Girard, J. Teruya-Feldstein, EC. Payabyab, GJ. Riely, VW. Rusch, MG. Kris, MF. Zakowski. Insulin-like growth factor-1 receptor expression in thymic malignancies. *J Thorac Oncol* 2010;5:1439-46
15. N. Girard, R. Lal, H. Wakelee, GJ. Riely, PJ. Loehrer. Chemotherapy definitions and policies for thymic malignancies. *J Thorac Oncol* 2011;6:S1749-55
16. L. Abouaf, N. Girard, T. Lefort, A. D'hombres, C. Tilikete, A. Vighetto, F. Mornex. Standard- Fractionated Radiotherapy for Optic Nerve Sheath Meningioma: Visual Outcome Is Predicted by Mean Eye Dose. *Int J Radiat Oncol Biol Phys* 2012; 82:1268-77
17. N. Girard, CS. Sima, DM Jackman, LV. Sequist, H. Chen, JC. Yang, H. Ji, B. Waltman, R. Rosell, M. Taron, MF. Zakowski, M. Ladanyi, G. Riely, W. Pao. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. *Eur Respir J* 2012 ; 39: 366-72
18. D. Lutringer-Magnin, N. Girard (co-first author), J. Cadranet, C. Leroux, E. Quoix, V. Cottin, C. Del Signore, MP. Lebitasy, G. Cordier, P. Vanhems, JF. Mornex. Professional exposure to goats increases the risk of pneumonic-type lung adenocarcinoma. Results of the IFCT-0504-Epidemio study. *PLoS One* 2012; 7:e37889

19. S. Couraud, A.B. Cortot, L. Greillier, V. Gounant, B. Mennequier, N. Girard, B. Besse, L. Brouchet, O. Castelnau, P. Frappé, G.R. Ferretti, L. Guittet, A. Khalil, P. Lefebure, F. Laurent, S. Liebart, O. Molinier, E. Quoix, M.P. Revel, B. Stach, P.J. Souquet, P. Thomas, J. Trédaniel, E. Lemarié, G. Zalcman, F. Barlési, B. Milleron. From randomized trials to the clinic: Is it time to implement individual lung cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French Intergroup (IFCT) and the Groupe d'Oncologie de Langue Française (GOLF). *Ann Oncol* 2013; 24:586-97

20. T. Vieira, N. Girard, M. Ung, I. Monnet, A. Cazes, P. Bonnette, M. Duruisseaux, J. Mazieres, M. Antoine, J. Cadranel, M. Wislez. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. *J Thorac Oncol* 2013;8:1574-7

21. VN. Aushev, IB. Zborovskaya, KK. Laktionov, N. Girard, MP. Cros, Z. Herceg, V. Krutovskikh.

Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. *PLoS One* 2013;8:e78649 11

22. S. Couraud, N. Girard, S. Erpeldinger, F. Gueyffier, G. Devouassoux, G. Llorca, P.J. Souquet; Lyon Lung

Cancer Screening Workgroup. Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in France. *Clin Lung Cancer* 2013;14:574-80

23. Toffart AC, Timsit JF, S. Couraud, P. Merle, D. Moro-Sibilot, M. Perol, B. Mastroianni, P.J. Souquet, N. Girard, G. Jeannin, P. Romand, P. Chatellain, A. Vesin, C. Brambilla, E. Brambilla.

Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). *Lung Cancer* 2014;83:182-8

24. N. Isambert, I. Ray-Coquard I, A. Italiano, M. Rios, P. Kerbrat, M. Gauthier, A. Blouet, L. Chaigneau, F. Duffaud, S. Piperno-Neumann, JE. Kurtz, N. Girard, O. Collard, E. Bompas, N. Penel, JO. Bay, C.

Guillemet, F. Collin, JY. Blay, A. Le Cesne, J. Thariat. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. *Eur J Cancer* 2014;50:128-36

25. AC. Toffart, X. Dhalluin, N. Girard, C. Chouaid, C. Audigier-Valette, M. Duruisseaux, B. Mennequier, A. Parrot, P. Fournel, D. Moro-Sibilot, JF. Timsit. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. *Intensive Care Med* 2015;41:164-5

26. CB. Confavreux, N. Girard, JB. Pialat, PP. Bringuier, M. Devouassoux-Shisheboran, JC. Rousseau, S. Isaac, F. Thivolet-Bejui, P. Clezardin, M. Brevet. Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). *Bonekey Rep* 2014;3:580

27. O. Bylicki, D. Rouvière, P. Cassier, L. Chalabreysse, A. Levard, JM. Maury, J. Margery, JY. Blay, J. Mazières, N. Girard. Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting. *J Thorac Oncol* 2015;10:309-15
28. N. Girard, S. Marchand-Adam, JM. Naccache, R. Borie, T. Urban, S. Jouneau, E. Marchand, AC. Ravel, L. Kiakouama, B. Etienne-Mastroianni, J. Cadranel, V. Cottin, JF. Cordier; Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients. *J Thorac Oncol* 2014;9:1162-70
29. S. Couraud, F. Vaca-Paniagua, S. Villar, J. Oliver, T. Schuster, H. Blanché, N. Girard, J. Trédaniel, L. Guilleminault, R. Gervais, N. Prim, M. Vincent, J. Margery, S. Larivé, P. Foucher, B. Duvert, M. Vallee, F. Le Calvez-Kelm, J. McKay, P. Missy, F. Morin, G. Zalcman, M. Olivier, PJ. Souquet; BioCAST/IFCT- 1002 investigators. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. *Clin Cancer Res* 2014;20:4613-24.
30. Marx A, Ströbel P, Badve SS, Chalabreysse L, Chan JK, Chen G, de Leval L, Detterbeck F, Girard N, Huang J, Kurrer MO, Lauriola L, Marino M, Matsuno Y, Molina TJ, Mukai K, Nicholson AG, Nonaka D, Rieker R, Rosai J, Ruffini E, Travis WD. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. *J Thorac Oncol* 2014;9:596-611
31. Girard N, Audigier-Valette C, Cortot AB, Menecier B, Debieuvre D, Planchard D, Zalcman G, Moro- Sibilot D, Cadranel J, Barlési F. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice? *Expert Rev Anticancer Ther* 2015;15:225-33
32. AC. Toffart, D. Moro-Sibilot, S. Couraud, P. Merle, M. Perol, N. Girard, PJ. Souquet, B. Mastroianni, G. Ferretti, P. Romand, P. Chatellain, A. Vesin, E. Brambilla, C. Brambilla, JF. Timsit. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study. *BMC Cancer* 2014;14:989
33. V. Fallet, R. Saffroy, N. Girard, J. Mazieres, S. Lantuejoul, T. Vieira, I. Rouquette, F. Thivolet-Bejui, M. Ung, V. Poulot, L. Schlick, D. Moro-Sibilot, M. Antoine, J. Cadranel, A. Lemoine, M. Wislez. Highthroughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. *Ann Oncol* 2015;26:1748-53
34. F. Le Loarer, S. Watson, G. Pierron, VT. de Montpreville, S. Ballet, N. Firmin, A. Auguste, D. Pissaloux, S. Boyault, S. Paindavoine, PJ. Dechelotte, B. Besse, JM. Vignaud, M. Brevet, E. Fadel, W. Richer, I. Treilleux, J. Masliah-Planchon, M. Devouassoux-Shisheboran, G. Zalcman, Y. Allory, F. Bourdeaut, F. Thivolet-Bejui, D. Ranchere-Vince, N. Girard, S. Lantuejoul, F. Galateau-Sallé, JM. Coindre, A. Leary, O. Delattre, JY. Blay, F. Tirode. SMARCA4 inactivation defines a group of

undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. *Nat Genet* 2015;47:1200-5 12

35. N. Girard, E. Ruffini, A. Marx, C. Faivre-Finn, S. Peters; ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015;26 Suppl 5:v40-55

36. C. Bernard, H. Frih, F. Pasquet, S. Kerever, Y. Jamilloux, F. Tronc, B. Guibert, S. Isaac, M. Devouassoux, L. Chalabreysse, C. Broussolle, P. Petiot, N. Girard, P. Sève. Thymoma associated with autoimmune diseases: 85 cases and literature review. *Autoimmun Rev* 2016;15:82-92

37. V. Thomas de Montpréville, L. Quilhot, L. Chalabreysse, A. De Muret, V. Hofman, S. Lantuéjoul, M. Parrens, MJ. Payan, I. Rouquette, V. Secq, N. Girard, B. Besse, A. Marx, TJ. Molina. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. *Pathol Res Pract* 2015;211:996-1002

38. C. Tissot, S. Couraud, R. Tanguy, PP. Bringuier, N. Girard, PJ. Souquet. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. *Lung Cancer* 2016;91:23-8

39. C. Rivoisy, B. Besse, N. Girard, B. Lioger, JF. Viallard, JC. Lega, P. Rullier, A. Perlat, D. Lerouge, C. Clement-Duchene, M. Ebbo, A. Bosseray, B. Godeau, O. Lambotte. Thymic Epithelial Tumor- Associated Cytopenia: A 10-Year Observational Study in France. *J Thorac Oncol* 2016. pii: S1556-0864(15)00210-5.

40. I. Monnet, C. Audigier-Valette, N. Girard, A. Vergnenègre, O. Molinier, PJ. Souquet, F. Blanchon, F. Bonnetain, N. Taguieva-Pioger, C. Lamour, M. Wislez. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study. *Lung Cancer* 2016;98:84-90.

41. J. Remon, N. Girard, J. Mazieres, E. Dansin, E. Pichon, L. Grellier, C. Dubos, CR. Lindsay, B. Besse.

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. *Lung Cancer* 2016;97:99-104.

42. S. Carras, F. Berger, L. Chalabreysse, E. Callet-Bauchut, JF. Cordier, G. Salles, N. Girard. Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. *Hematol Oncol* 2016. doi: 10.1002/hon.2301.

43. FC. Detterbeck, WA. Franklin, AG. Nicholson, N. Girard, DA. Arenberg, WD. Travis, PJ. Mazzone, EM. Marom, JS. Donington, LT. Tanoue, VW. Rusch, H. Asamura, R. Rami-Porta; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:651-65.

44. FC. Detterbeck, V. Bolejack, DA. Arenberg, J. Crowley, JS. Donington, WA. Franklin, N. Girard, EM. Marom, PJ. Mazzone, AG. Nicholson, VW. Rusch, LT. Tanoue, WD. Travis, H. Asamura, R. Rami-Porta; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:681-92.
45. FC. Detterbeck, AG. Nicholson, WA. Franklin, EM. Marom, WD. Travis, N. Girard, DA. Arenberg, V. Bolejack, JS. Donington, PJ. Mazzone, LT. Tanoue, VW. Rusch, J. Crowley, H. Asamura, R. Rami-Porta; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *J Thorac Oncol* 2016;11:639-50.
46. FC. Detterbeck, EM. Marom, DA. Arenberg, WA. Franklin, AG. Nicholson, WD. Travis, N. Girard, PJ. Mazzone, JS. Donington, LT. Tanoue, VW. Rusch, H. Asamura, R. Rami-Porta; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *J Thorac Oncol* 2016;11:666-80
47. N. Girard, J. Corral, D. Cortinovis, DF. Heigener. Second-Line Treatment Selection in Patients With 13 Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians. *Clin Lung Cancer* 2016; S1525-7304(16)30347-3
48. Lhote R, Haroche J, Duron L, Girard N, Lafourcade MP, Martin M, Begueret H, Taytard A, Capron F, Grenier P, Piette JC, Cohen-Aubart F, Amoura Z. Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature. *Immunol Res* 2016, sous presse
49. C. Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, C. Massabeau, C. Clément- Duchene, G. Massard, V. Westeel, X. Quantin, Y. Oulkhair, S. Danhier, D. Lerouge, R. Tanguy, F. Thillays, C. Le Pechoux, B. Dubray, L. Thiberville, B. Besse, N. Girard. Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. *J Thorac Oncol* 2017. pii: S1556-0864(17)30654-8

50. M. Delaunay, J. Cadranel, A. Lusque, N. Meyer, V. Gounaut, D. Moro-Sibilot, JM. Michot, J. Raimbourg, N. Girard, F. Guisier, D. Planchard, AC. Metivier, P. Tomasini, E. Dansin, M. Pérol, M. Campana, O. Gautschi, M. Früh, JD. Fumet, C. Audigier-Valette, S. Couraud, S. Dalle, MT. Leccia, M. Jaffro, S. Collot, G. Prévot, J. Milia, J. Mazieres. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. *Eur Respir J* 2017;50(2)
51. A. Meurgey, N. Girard, C. Merveilleux du Vignaux, JM. Maury, F. Tronc, F. Thivolet-Bejui, L. Chalabreysse. Assessment of the ITMIG Statement on the WHO Histological Classification and of the Eighth TNM Staging of Thymic Epithelial Tumors of a Series of 188 Thymic Epithelial Tumors. *J Thorac Oncol* 2017. pii: S1556-0864(17)30572-5
52. R. Saffroy, V. Fallet, N. Girard, J. Mazieres, DM. Sibilot, S. Lantuejoul, I. Rouquette, F. Thivolet-Bejui, T. Vieira, M. Antoine, J. Cadranel, A. Lemoine, M. Wislez. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. *Oncotarget* 2017;8:42428-42437
53. JM. Maury, N. Girard, M. Tabutin, R. Grima, L. Chalabreysse, I. Pavlakovic, A. Sayag-Beaujard, C. Leroux, PJ. Souquet, O. Glehen, F. Tronc. Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma. *Lung Cancer* 2017;108:1-6
54. M. Gomes, F. Archer, N. Girard, B. Gineys, C. Dolmazon, A. Bobet Erny, JF. Mornex, C. Leroux. Blocked expression of key genes of the angiogenic pathway in JSRV-induced pulmonary adenocarcinomas. *Vet Res* 2017;48:76
55. RJ. Korst, S. Fernando, AC. Catlin, JR. Rutledge, N. Girard, J. Huang, F. Detterbeck; Contributors to the International Thymic Malignancy Interest Group (ITMIG) Prospective Database. Positron Emission Tomography in Thymic Tumors: Analysis Using a Prospective Research Database. *Ann Thorac Surg* 2017;104:1815-1820
56. S. Baldacci, J. Mazieres, P. Tomasini, N. Girard, F. Guisier, C. Audigier-Valette, I. Monnet, M. Wislez, M. Pérol, P. Do, E. Dansin, C. Leduc, E. Giroux Leprieur, D. Moro-Sibilot, D. Tulasne, Z. Kherrouche, J. Labreuche, AB. Cortot. Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. *Oncotarget* 2017;8:105103-105114
57. FX. Danlos, AL. Voisin, V. Dyeve, JM. Michot, E. Routier, L. Taillade, S. Champiat, S. Aspeslagh, J. Haroche, L. Albiges, C. Massard, N. Girard, S. Dalle, B. Besse, S. Laghouati, JC. Soria, C. Mateus, C. Robert, E. Lanoy, A. Marabelle, O. Lambotte. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. *Eur J Cancer* 2018;91:21-29

58. M. Radovich, CR. Pickering, I. Felau, G. Ha, H. Zhang, H. Jo, KA. Hoadley, P. Anur, J. Zhang, M. McLellan, R. Bowlby, T. Matthew, L. Danilova, AM. Hegde, J. Kim, MDM. Leiserson, G. Sethi, C. Lu, M. Ryan, X. Su, AD. Cherniack, G. Robertson, R. Akbani, P. Spellman, JN. Weinstein, DN. Hayes, B. Raphael, T. Lichtenberg, K. Leraas, JC. Zenklusen; Cancer Genome Atlas Network, J. Fujimoto, C. Scapulatempo-Neto, AL. Moreira, D. Hwang, J. Huang, M. Marino, R. Korst, G. Giaccone, Y. Gokmen-Polar, S. Badve, A. Rajan, P. Ströbel, N. Girard, MS. Tsao, A. Marx, AS. Tsao, PJ. Loehrer. The Integrated Genomic Landscape of Thymic Epithelial Tumors. *Cancer Cell* 2018;33:244-258
59. P. Serra, A. Petat, JM. Maury, F. Thivolet-Bejui, L. Chalabreysse, M. Barritault, N. Ebran, G. Milano, N. Girard, M. Brevet. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma. *Lung Cancer* 2018;118:62-68
60. S. Lantuejoul, J. Adam, N. Girard, M. Duruisseaux, A. Mansuet-Lupo, A. Cazes, I. Rouquette, L. Gibault, 14 S. Garcia, M. Antoine, JM. Vignaud, F. Galateau-Sallé, C. Sagan, C. Badoual, F. Penault-Llorca, D. Damotte. PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists. *Ann Pathol* 2018;38:110-125
61. A. Levy, C. Faivre-Finn, B. Hasan, E. De Maio, AS. Berghoff, N. Girard, L. Greillier, S. Lantuejoul, M. O'Brien, M. Reck, AC. Dingemans, S. Novello, T. Berghmans, B. Besse, L. Hendriks; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG). Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. *Eur J Cancer* 2018;93:37-46
62. CB. Confavreux, JB. Pialat, A. Bellière, M. Brevet, C. Decroisette, A. Tescau, J. Wegrzyn, C. Barrey, F. Mornex, PJ. Souquet, N. Girard. Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management. *Joint Bone Spine* 2018. pii: S1297-319X(18)30048-4.
63. F. Galateau Salle, N. Le Stang, AG. Nicholson, D. Pissaloux, A. Churg, S. Klebe, VL. Roggli, HD. Tazelaar, JM. Vignaud, R. Attanoos, MB. Beasley, H. Begueret, F. Capron, L. Chirieac, MC. Copin, S. Dacic, C. Danel, A. Foulet-Roge, A. Gibbs, S. Giusiano-Courcambeck, K. Hiroshima, V. Hofman, AN. Husain, K. Kerr, A. Marchevsky, K. Nabeshima, JM. Picquenot, I. Rouquette, C. Sagan, JL. Sauter, F. Thivolet, WD. Travis, MS. Tsao, B. Weynand, F. Damiola, AS. Scherpereel, JC. Pairon, S. Lantuejoul, V. Rusch, N. Girard. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. *J Thorac Oncol* 2018;13:1189-1203

64. L. Chambard, N. Girard, E. Ollier, JC. Rousseau, F. Duboeuf, MC. Carlier, M. Brevet, P. Szulc, JB. Pialat, J. Wegrzyn, P. Clezardin, CB. Confavreux. Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. *Bone* 2018;108:202-209
65. VM. Braud, J. Biton, E. Becht, S. Knockaert, A. Mansuet-Lupo, E. Cosson, D. Damotte, M. Alifano, P. Validire, F. Anjuère, I. Cremer, N. Girard, D. Gossot, A. Seguin-Givelet, MC. Dieu-Nosjean, C. Germain. Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. *Oncoimmunology* 2018;7:e1423184
66. C. Merveilleux du Vignaux, E. Dansin, L. Mhanna, L. Greillier, E. Pichon, M. Kerjouan, C. Clément- Duchêne, B. Mennequier, V. Westeel, M. Robert, X. Quantin, G. Zalcman, L. Thiberville, H. Lena, T. Molina, F. Calcagno, P. Fournel, J. Mazières, B. Besse, N. Girard. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. *J Thorac Oncol* 2018;13:1762-1770
67. M. Duruisseaux, A. Martínez-Cardús, ME. Calleja-Cervantes, S. Moran, M. Castro de Moura, V. Davalos, D. Piñeyro, M. Sanchez-Cespedes, N. Girard, M. Brevet, E. Giroux-Leprieur, C. Dumenil, M. Pradotto, P. Bironzo, E. Capelletto, S. Novello, A. Cortot, MC. Copin, N. Karachaliou, M. Gonzalez-Cao, S. Peralta, LM. Montuenga, I. Gil-Bazo, I. Baraibar, MD. Lozano, M. Varela, JC. Ruffinelli, R. Palmero, E. Nadal, T. Moran, L. Perez, I. Ramos, Q. Xiao, AF. Fernandez, MF. Fraga, M. Gut, I. Gut, C. Teixidó, N. Vilariño, A. Prat, N. Reguart, A. Benito, P. Garrido, I. Barragan, JF. Emile, R. Rosell, E. Brambilla, M. Esteller. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. *Lancet Respir Med* 2018;6:771-781
68. N. Girard, D. Cozzone, L. de Leotoing, C. Tournier, A. Vainchtock, B. Tehard, AB. Cortot. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. *ESMO Open* 2018;3:e000414
69. L. Ferrer, M. Giaj Levra, M. Brevet, M. Antoine, J. Mazieres, G. Rossi, R. Chiari, V. Westeel, M. Poudenx, J. Letreut, R. Gervais, G. Osman, N. Girard, AC. Toffart, S. Novello, D. Moro-Sibilot. A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. *J Thorac Oncol* 2019;14:130-134
70. X. Mignard, AM. Ruppert, M. Antoine, J. Vasseur, N. Girard, J. Mazières, D. Moro-Sibilot, V. Fallet, N. Rabbe, F. Thivolet-Bejui, I. Rouquette, S. Lantuejoul, A. Cortot, R. Saffroy, J. Cadranel, A. Lemoine, M. Wislez. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. *J Thorac Oncol* 2018;13:1962-1967
71. JM. Maury, G. Drevet, S. Collaud, R. Grima, I. Pavlakovic, P. Rosamel, L. Chalabreysse, N. Girard, F. Tronc. Cytoreductive Pleurectomy and Intra Thoracic Chemo Hyperthermia for Pleural Relapse of Thymomas. *Ann Thorac Surg* 2018. pii: S0003-4975(18)31305-5 15

72. C. Lafitte C, Etienne-Mastroianni B, Fournel C, Natoli L, Foucaut AM, Girard N. Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer. *Lung Cancer* 2018;124:143-147
73. T. Berghmans, V. Durieux, S. Holbrechts, C. Jungels, JJ. Lafitte, AP. Meert, L. Moretti, S. Ocak, M. Roelandts, N. Girard. Systemic treatments for thymoma and thymic carcinoma: A systematic review. *Lung Cancer* 2018;126:25-31
74. S. Peters, U. Dafni, M. Boyer, D. De Ruysscher, C. Faivre-Finn, E. Felip, P. Garrido, N. Girard, M. Guckenberger, J. Haanen, C. Le Pechoux, F. Mornex, M. Ozsahin, L. Paz-Ares, D. Planchard, D. Raben, S. Ramalingam, M. Reck, E. Smit, R. Stahel, A. Stenzinger, C. Swanton, S. Vallone, M. Garassino. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). *Ann Oncol* 2019. doi: 10.1093/annonc/mdy553.
-